Peptide intelligence without
the bullsh*t.

Semaglutide is an FDA-approved GLP-1 receptor agonist with the strongest clinical evidence of any peptide on the market. STEP trials: 15–17% body weight reduction. SELECT trial: 20% cardiovascular risk reduction in non-diabetic overweight patients. The defining weight-loss drug of the 2020s.

Tirzepatide is a dual GLP-1/GIP receptor agonist consistently outperforming semaglutide in trials. SURMOUNT-1: 20.9% weight loss. FDA approved as Mounjaro (T2D) and Zepbound (obesity). Current efficacy benchmark for GLP-1 class therapies.

BPC-157 is a pentadecapeptide derived from a gastric juice protective protein. Over 100 animal studies demonstrate broad tissue-protective and healing effects. No completed human RCTs, but Phase II IBD trials have been conducted. One of the most-studied research peptides.

Bremelanotide (PT-141) is FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. Acts centrally on brain melanocortin pathways governing sexual motivation — unlike PDE5 inhibitors which work peripherally. Also used off-label for male ED.

Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) approved for pediatric growth hormone deficiency. It stimulates pituitary GH release through the body's own feedback mechanisms, making it a physiologically regulated alternative to exogenous HGH.

Thymosin Alpha-1 is one of the most clinically validated immune peptides. Approved as Zadaxin in 35+ countries for hepatitis B/C and cancer immunotherapy. Meta-analysis of 7 RCTs shows significant mortality reduction in sepsis. Gold standard immune peptide.